Breast Cancer Liquid Biopsy Market Research

Global Breast Cancer Liquid Biopsy Market:

The global breast cancer liquid biopsy market size reached US$ 130.4 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 497.2 Million by 2032, exhibiting a growth rate (CAGR) of 15.5% during 2024-2032. The rising prevalence of breast cancer, shift towards non-invasive diagnostic methods, ongoing technological advancements, and surging investment in cancer research, are primarily driving the market's growth.

Breast Cancer Liquid Biopsy Market Analysis:

• Major Market Drivers: The growing prevalence of breast cancer along with the escalating demand for non-invasive medical procedures is primarily driving the global breast cancer liquid biopsy market demand. In addition to this, the rising consumer awareness towards numerous benefits associated with the liquid biopsy technique, including quicker results, lower cost, minimal health risk, non-invasiveness, etc., is also augmenting the market growth.
• Key Market Trends: The increasing number of government and private reimbursement policies for breast cancer biopsy and other related medical procedures is creating a positive outlook for the market. Additionally, the emerging trend of personalized therapeutics coupled with the widespread adoption of polymerase chain reaction (PCR) and next-generation sequencing (NGS) for cancer detection will continue to drive the global breast cancer liquid biopsy market in the coming years.
• Competitive Landscape: Some of the prominent breast cancer liquid biopsy market companies include Biocept Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche AG, Fluxion Biosciences Inc., Guardant Health Inc., Illumina Inc., Menarini Silicon Biosystems (The Menarini Group), NeoGenomics Laboratories Inc., Qiagen, and Sysmex Europe SE (Sysmex Corporation), among many others.
• Geographical Trends: According to the breast cancer liquid biopsy market forecast report, North America currently dominates the overall market. Breast cancer remains one of the most common cancers affecting women in North America. The increasing number of cases fuels the demand for more effective and less invasive diagnostic tools like liquid biopsies.
• Challenges and Opportunities: The high costs of developing and validating liquid biopsy tests and regulatory hurdles are hampering the market's growth. However, liquid biopsies can be used to detect minimal residual disease (MRD), where small amounts of cancer remain after treatment and may eventually cause a recurrence. This capability presents a major opportunity in post-treatment monitoring.
   

Breast Cancer Liquid Biopsy Market Trends:

Increasing Prevalence of Breast Cancer

The increasing global prevalence of breast cancer is one of the primary drivers. For instance, according to the World Health Organization (WHO), in 2022, nearly 2.3 million women were diagnosed with breast cancer, and approximately 670,000 died worldwide. Similarly, according to the National Breast Cancer Foundation, in the United States, 1 out of every 8 women will be diagnosed with breast cancer during their lifetime. In 2024, an estimated 310,720 women and 2,800 males will be diagnosed with invasive breast cancer. As breast cancer remains one of the most common cancers among women worldwide, the demand for early detection and monitoring solutions, like liquid biopsy, is rising. These factors are expected to propel the breast cancer liquid biopsy market share in the coming years.

Focus on Early Detection

Early detection of breast cancer significantly improves patient outcomes, and liquid biopsy allows for earlier detection than some traditional imaging methods. For instance, according to an article published by the National Library of Medicine, LB has demonstrated potential in diagnosing cancer at an early stage, tracking tumor growth and recurrence, and predicting patient response to therapy. It also enables continuous monitoring, which is essential for tracking disease progression and treatment response, making it an essential tool in modern oncology. These factors further positively influence the breast cancer liquid biopsy market forecast.

Product Innovations

Innovations in genomic sequencing, molecular biology, and bioinformatics are enhancing the sensitivity, specificity, and accuracy of liquid biopsy techniques. For instance, in November 2023, Illumina Inc., a DNA sequencing and array-based technology business, developed an improved version of their distributed liquid biopsy assay for genomic profiling. The new TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2) is a research assay that allows for non-invasive comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) from blood. These advancements help in early cancer detection, monitoring treatment efficacy, and identifying resistance mutations, which drives the adoption of liquid biopsy in clinical settings, thereby boosting the breast cancer liquid biopsy market growth.

Global Breast Cancer Liquid Biopsy Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global breast cancer liquid biopsy market report, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on product services, circulating biomarker, and end user.

Breakup by Product Services:

• Reagent Kits
• Instruments
• Services
   

Currently, reagent kits account for the majority of the global market share

The report has provided a detailed breakup and analysis of the breast cancer liquid biopsy market based on the product services. This includes reagent kits, instruments, and services. According to the report, reagent kits account for the majority of the global market share.

According to the breast cancer liquid biopsy market outlook, the increasing global incidence of breast cancer has heightened the need for better diagnostic, monitoring, and screening tools. As liquid biopsy becomes more commonly used, the demand for reagent kits that support these tests rises proportionally. Moreover, traditional tissue biopsies are invasive and can cause discomfort and complications. Liquid biopsy offers a non-invasive alternative, which is gaining popularity for both diagnostic and treatment monitoring purposes. This shift is a key driver for reagent kits used in liquid biopsy procedures, such as those for detecting circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs).

Breakup by Circulating Biomarker:

• Circulating Tumor Cells (CTCs)
• Cell-Free DNA (cfDNA)
• Extracellular Vesicles (EVs)
• Others
   

The report has provided a detailed breakup and analysis of the breast cancer liquid biopsy market based on the circulating biomarker. This includes circulating tumor cells (CTCs), cell-free DNA (cfDNA), extracellular vesicles (EVs), and others.

According to the breast cancer liquid biopsy market analysis report, CTCs are cancer cells that have shed from the primary tumor into the bloodstream. The presence of CTCs in the blood correlates with disease stage and prognosis. Higher numbers of CTCs are often associated with advanced cancer and poorer outcomes. Moreover, cfDNA consists of small fragments of DNA released from tumor cells (also referred to as circulating tumor DNA or ctDNA) and other cells into the bloodstream. Moreover, analysis of cfDNA allows for the detection of specific mutations, such as those in the PIK3CA gene, TP53, or ESR1, which can guide treatment choices, especially for targeted therapies. Furthermore, extracellular vesicles (such as exosomes and microvesicles) are small membrane-bound particles released by cells, including cancer cells, into the bloodstream. EVs contain a variety of biomolecules, including proteins, RNA, DNA, and lipids, and can play a role in cell-to-cell communication.

Breakup by End User:

• Reference Laboratories
• Hospitals and Physician Laboratories
• Others
   

The report has provided a detailed breakup and analysis of the breast cancer liquid biopsy market based on the end user. This includes reference laboratories, hospitals and physician laboratories, and others.

According to the breast cancer liquid biopsy market outlook report, reference labs often have access to the most cutting-edge technologies in liquid biopsy, including next-generation sequencing (NGS) and circulating tumor DNA (ctDNA) analysis. Their advanced infrastructure attracts demand from hospitals and physician labs that do not have these capabilities. Moreover, large hospitals, especially those with dedicated oncology centers, have a high volume of breast cancer patients requiring regular monitoring. Liquid biopsy offers a less invasive, faster alternative to traditional tissue biopsies for diagnosis, treatment monitoring, and recurrence detection. Furthermore, physical labs are often the first point of care for breast cancer screening. Liquid biopsies provide a more accessible and less invasive option for patients at high risk of breast cancer, allowing for earlier detection and intervention.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

North America currently dominates the global market

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America dominates the global market.

According to the breast cancer liquid biopsy market statistics, breast cancer remains one of the most common cancers among women in North America, driving demand for improved diagnostic tools. Moreover, liquid biopsies offer a non-invasive alternative to traditional tissue biopsies, which can be painful, risky, and difficult to perform, especially in advanced cancer cases. As a simple blood test, liquid biopsy is more appealing to patients, contributing to its growing adoption. Besides this, advances in liquid biopsy technologies, including next-generation sequencing (NGS), PCR-based methods, and improved ctDNA and CTC (circulating tumor cells) detection platforms, have significantly increased the accuracy and sensitivity of these tests. These innovations are driving wider clinical adoption of liquid biopsy for breast cancer diagnosis and monitoring.

Competitive Landscape:

The breast cancer liquid biopsy market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market companies have also been provided. Some of the key players in the market include: 

• Biocept Inc.
• Bio-Rad Laboratories Inc.
• F. Hoffmann-La Roche AG
• Fluxion Biosciences Inc.
• Guardant Health Inc.
• Illumina Inc.
• Menarini Silicon Biosystems (The Menarini Group)
• NeoGenomics Laboratories Inc.
• Qiagen
• Sysmex Europe SE (Sysmex Corporation)
   

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Breast Cancer Liquid Biopsy Market Recent Developments:

• September 2024: Strand Life Sciences, a Reliance Industries subsidiary, introduced the Somatic Advantage 74 Liquid Biopsy (SA74 LB) Test, which detects circulating tumor DNA in cancer patients' blood.
• May 2024: Personalis, Inc., advanced genomics for precision oncology provider, announced that Tempus will begin commercialization efforts for NeXT Personal, Personalis' ultra-sensitive, whole genome-based liquid biopsy assay for detecting minimal residual disease (MRD) and cancer recurrence.
• February 2024: The Continental Hospitals launched the Early Detection Liquid Biopsy Test, a cancer detection mechanism to enable early cancer detection.

Breast Cancer Liquid Biopsy Market Report Scope:

Key Benefits for Stakeholders:

• IMARC's report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the breast cancer liquid biopsy market from 2018-2032.
• The research study provides the latest information on the market drivers, challenges, and opportunities in the global breast cancer liquid biopsy market.
• The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
• Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the breast cancer liquid biopsy industry and its attractiveness.
• The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.